The Experts below are selected from a list of 6867 Experts worldwide ranked by ideXlab platform
Xie Hui-zhong - One of the best experts on this subject based on the ideXlab platform.
-
Analysis of helicobacter pylori detection rate in Uygur and chinese Duodenum Disease
Journal of Xinjiang Medical University, 2007Co-Authors: Xie Hui-zhongAbstract:Objective: To study Helicobacter pylori infection rate in Uygur and Hhan patients with gastro-Duodenum Disease,provide theory idea to H.pylori detection and eradication in clinical medicine.Method: Serodiagnosis for determining H.pylori infection status by H.pylori RUT and Giemsa stain examination for 309 Han and Uygur patients were done.If H.pylori RUT and Giemsa stain all positive,this was regarded as H.pylori positive.Compared Han and Uygur patients with H.pylori infection rate,age,gender.Results: The duodenal ulcer(Du) patients were more younge and gastric ulcer(Gu) patients more olden compare with chronic gastritis(CG) patients.(1) The H.pylori positive rate were 44.06%(52/118) in Han nationality with CG patients,and 44.59%(33/74) in Uygur nationality with CG patients.There was no statistically significance(χ2=0.005,P=0.943).(2) The H.pylori positive rate was 52.50%(21/40) in Han nationality with Du patients,41.18%(14/34)in Uygur nationality with Du patients.There was no statistically significance(χ2=0.945,P=0.331).(3) The H.pylori positive rate was 27.27%(6/22) in Han nationality with Gu patients,55.00%(11/20) in Uygur nationality with Gu patients.There was no statistically significance(χ2=3.343,P=0.067).Conclusion: As can be seen from the study,we believe that there are no significance in H.pylori positive rate in Han and Uygur patients.Identical H.pylori exam method and therapy strategy can be used to all same Uygur and Chinese gastro-Duodenum Disease.
Tetsuro Inokuma - One of the best experts on this subject based on the ideXlab platform.
-
Methotrexate-associated lymphoproliferative disorder in the stomach and Duodenum: a case report
BMC Gastroenterology, 2019Co-Authors: Haruka Toyonaga, Masashi Fukushima, Naoto Shimeno, Tetsuro InokumaAbstract:Background Methotrexate-associated lymphoproliferative disorder (MTX-LPD) can present as a benign lymphoid proliferation or a malignant lymphoma in patients taking MTX. Almost 50% of MTX-LPD cases show spontaneous remission after withdrawal of MTX treatment. Studies have suggested that the hyper-immune state of rheumatoid arthritis, the immunosuppressive state associated with MTX, and the carcinogenicity of the Epstein-Barr virus might contribute to MTX-LPD development. Although most cases of MTX-LPD occur at extranodal sites, few cases of MTX-LPD affecting the stomach and Duodenum have been reported. To our knowledge, no other study has reported on the endoscopic observations of dramatic withdrawal and appearance of multiple digestive tract lesions in a short period of time. Herein, we report the clinical course and imaging findings of our case, which may be useful for understanding the pathological condition of MTX-LPD. Case presentation We describe the case of a 70-year-old woman with MTX-LPD of the stomach and Duodenum. Disease regression was temporarily achieved after cessation of MTX treatment; however, it subsequently recurred, and complete response was only achieved after six cycles of rituximab, cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisolone (R-CHOP) chemotherapy. Conclusions The first-choice therapy for patients taking MTX who develop suspected MTX-LPD should be the withdrawal of MTX treatment. Even after remission is achieved, patients should be kept under careful observation, and if the Disease recurs, chemotherapy should be commenced promptly.
Zhu Jinshui - One of the best experts on this subject based on the ideXlab platform.
-
Progression of interaction between IL-18 and stomach Duodenum Disease
International Journal of Digestive Diseases, 2008Co-Authors: Zhang Wei-ping, Zhu JinshuiAbstract:Since 1995 the Japanese scholars discovered cytokine of IL-18,the results of the research have discovered that IL-18 are connected with multitudinous clinical Diseases,such as autoimmune Disease,allergic disorder,mental disorder,myocardial Disease and hepatic injury.Early there are reports about the chronic gastritis patient has IL-18 mRNA expression in human gastric biopsy specimens.This article reviewed the progression of the IL-18 own characteristic and its interaction with the stomach Duodenum Disease.
Haruka Toyonaga - One of the best experts on this subject based on the ideXlab platform.
-
Methotrexate-associated lymphoproliferative disorder in the stomach and Duodenum: a case report
BMC Gastroenterology, 2019Co-Authors: Haruka Toyonaga, Masashi Fukushima, Naoto Shimeno, Tetsuro InokumaAbstract:Background Methotrexate-associated lymphoproliferative disorder (MTX-LPD) can present as a benign lymphoid proliferation or a malignant lymphoma in patients taking MTX. Almost 50% of MTX-LPD cases show spontaneous remission after withdrawal of MTX treatment. Studies have suggested that the hyper-immune state of rheumatoid arthritis, the immunosuppressive state associated with MTX, and the carcinogenicity of the Epstein-Barr virus might contribute to MTX-LPD development. Although most cases of MTX-LPD occur at extranodal sites, few cases of MTX-LPD affecting the stomach and Duodenum have been reported. To our knowledge, no other study has reported on the endoscopic observations of dramatic withdrawal and appearance of multiple digestive tract lesions in a short period of time. Herein, we report the clinical course and imaging findings of our case, which may be useful for understanding the pathological condition of MTX-LPD. Case presentation We describe the case of a 70-year-old woman with MTX-LPD of the stomach and Duodenum. Disease regression was temporarily achieved after cessation of MTX treatment; however, it subsequently recurred, and complete response was only achieved after six cycles of rituximab, cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisolone (R-CHOP) chemotherapy. Conclusions The first-choice therapy for patients taking MTX who develop suspected MTX-LPD should be the withdrawal of MTX treatment. Even after remission is achieved, patients should be kept under careful observation, and if the Disease recurs, chemotherapy should be commenced promptly.
Ao Xiao-ming - One of the best experts on this subject based on the ideXlab platform.
-
The clinical analysis of triplicate medical treatmeat on 32 cases of Helicobater pylori positive stomach and Duodenum Disease
Hebei Medicine, 2003Co-Authors: Ao Xiao-mingAbstract:Objective:To explore the scheme of eradicate Helicobacter pylori(Hp) of higher eradication rate,lower price, better compliance. Methods:It was performed accompany Helicobacter pylori infection digestive ulcer and dissipated gastritis 55 cases by endoscopy with biopsy histology .were randomly assigened to two group : A groups,compound ranitidine triple therapy groups(n=32) or B groups,omeprazole triple therapy groups(n=27),the course of reatment is seven days.After 6 or 8 weeks on the treatment of Hp,check Hp with endoscopy biopsy .Results: HP Eradication rate of two groups was each other 84.3% and 85.2%,the healing rate was each other 76.0% and 78.9%,dissipated gastritis healing rate was each other 85.7% and 87.5%,incidence of adverse effects was each other 15.6% and 11.1%. Conclusions:The scheme of compound ranitidine one-week tripletherapy groups was higher eradication rate, shorter course of treatment, cheeper and less adverse effects etc. characteristic.
